Genmab Announces DuoBody Platform Collaboration With Kyowa Hakko Kirin

Company Announcement

- DuoBody® research collaboration with Kyowa Hakko Kirin - Genmab's fourth DuoBody technology collaboration

Genmab A/S (Copenhagen:GEN) announced today a research collaboration with Kyowa Hakko Kirin Co., Ltd. to create bispecific antibodies using Genmab's DuoBody technology. If successful, the parties may decide to enter into a license agreement to develop a new DuoBody product.

"We have made excellent progress in partnering our innovative DuoBody technology platform, with the Kyowa Hakko Kirin agreement marking our fourth DuoBody platform collaboration within the past year. We believe this keen level of interest on the part of top tier pharmaceutical companies clearly illustrates the promise of bispecific antibodies created with the DuoBody platform, and also demonstrates the technology's compatibility with a range of antibody-platforms," said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

The financial terms of the agreement have not been disclosed.  This agreement will not have a material impact on Genmab's 2012 financial guidance.

About the DuoBody Platform The DuoBody platform is an innovative platform for the discovery and development of bispecific antibodies that may improve antibody therapy of cancer, autoimmune, infectious and central nervous system disease. Bispecific antibodies bind to two different epitopes either on the same, or on different targets (also known as dual-targeting) which may improve the antibodies' specificity and efficacy in inactivating the disease targets. DuoBody molecules are unique in combining the benefits of bispecificity with the strengths of conventional antibodies which allows DuoBody molecules to be administered and dosed as other antibody therapeutics. Genmab's DuoBody platform generates bispecific antibodies via a fast and broadly applicable process which is easily performed at standard bench, as well as commercial, manufacturing scale.

About Genmab A/S Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer.  Founded in 1999, the company's first marketed antibody, ofatumumab (Arzerra(r)), was approved to treat chronic lymphocytic leukemia in patients who are refractory to fludarabine and alemtuzumab after less than eight years in development.  Genmab's validated and next generation antibody technologies are expected to provide a steady stream of future product candidates.  Partnering of innovative product candidates and technologies is a key focus of Genmab's strategy and the company has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com.

Contact: Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications T: [phone]; M: [phone]; E: [e-mail]

This Company Announcement contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on www.genmab.com. Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements in relation to actual results, unless required by law.

Genmab®; the Y-shaped Genmab logo®; HuMax®; HuMax-CD20®; DuoBody® and UniBody® are all trademarks of Genmab A/S. Arzerra® is a trademark of GlaxoSmithKline.

Company Announcement no. 32 CVR no. 2102 3884

Genmab A/S Bredgade 34E 1260 Copenhagen K Denmark